Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15563650500357677 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Toxicology Investigators Consortium 2023 Annual Report.
J Med Toxicol
October 2024
American College of Medical Toxicology, 10645 N Tatum Blvd., Suite 200-111, Phoenix, AZ, 85028, USA.
Article Synopsis
- The American College of Medical Toxicology's Toxicology Investigators Consortium has been maintaining a national case registry since 2010, documenting patient consultations in hospitals and clinics regarding medical toxicology.
- In 2023, the registry recorded data from 7,392 patients, bringing the total number of cases since its inception to 102,331 across 36 sites with 61 healthcare facilities.
- Ethanol emerged as the most common exposure agent in 2023, followed by opioids and non-opioid analgesics, with a reported 98 fatalities (1.3% case fatality rate) and analyses of demographics and trends in toxicology consultations.
Letter in Response to Oral and Transdermal Rivastigmine for the Treatment of Anticholinergic Delirium: A Case Report.
J Emerg Med
February 2024
Section of Medical Toxicology, Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado; Rocky Mountain Poison and Drug Safety, Denver, Colorado.
Treatment of pediatric antimuscarinic delirium with oral rivastigmine.
Oxf Med Case Reports
September 2023
Department of Emergency Medicine, Detroit Medical Center, Detroit, MI, USA.
Antimuscarinic drug toxicity is a common pediatric emergency, which produces central and peripheral symptoms. Treatment of agitation and hyperactive antimuscarinic delirium, with first-line agents like cholinesterase inhibitors or benzodiazepines, is imperative to prevent severe toxicity. Intravenous physostigmine salicylate is a cholinesterase inhibitor that is commonly used to treat central antimuscarinic delirium.
View Article and Find Full Text PDFShortages of agents used to treat antimuscarinic delirium.
Am J Emerg Med
May 2023
National Capital Poison Center, 3201 New Mexico Avenue, Suite 310, Washington, DC 20016, USA; Department of Emergency Medicine, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, USA.
Introduction: Antimuscarinic delirium (AD), a potentially life-threatening condition frequently encountered by emergency physicians, results from poisoning with antimuscarinic agents. Treatment with physostigmine and benzodiazepines is the mainstay of pharmacotherapy, and use of dexmedetomidine and non-physostigmine centrally-acting acetylcholinesterase inhibitors (cAChEi) such as rivastigmine has also been described. Unfortunately, these medications are subject to drug shortages which negatively impact the ability to provide appropriate pharmacologic treatment of patients with AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!